Interleukin 18: Friend or foe in cancer

Giuseppe Palma, Antonio Barbieri, Sabrina Bimonte, Marco Palla, Silvia Zappavigna, Michele Caraglia, Paolo A. Ascierto, Gennaro Ciliberto, Claudio Arra

Research output: Contribution to journalArticle


In the last few years, the field of tumor immunology has significantly expanded and its boundaries, never particularly clear, have become less distinct. Although the immune system plays an important role in controlling tumor growth, it has also become clear that tumor growth can be promoted by inflammatory immune responses. A good example that exemplifies the ambiguous role of the immune system in cancer progression is represented by interleukin 18 (IL-18) that was first identified as an interferon-γ-inducing factor (IGIF) involved in T helper type-1 (Th1) immune response. The expression and secretion of IL-18 have been observed in various cell types from immune cells to circulating cancer cells. In this review we highlighted the multiple roles played by IL-18 in immune regulation, cancer progression and angiogenesis and the clinical potential that may result from such understanding.

Original languageEnglish
Pages (from-to)296-303
Number of pages8
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number2
Publication statusPublished - Dec 2013


  • Immune regulation
  • Tumor immunology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Fingerprint Dive into the research topics of 'Interleukin 18: Friend or foe in cancer'. Together they form a unique fingerprint.

  • Cite this